Literature DB >> 16954231

Enhanced patient serum immunoreactivity to recombinant Mycobacterium tuberculosis CFP32 produced in the yeast Pichia pastoris compared to Escherichia coli and its potential for serodiagnosis of tuberculosis.

Chaouki Benabdesselem1, Dahmani M Fathallah, Richard C Huard, Hongxia Zhu, Mohamed Ali Jarboui, Koussay Dellagi, John L Ho, Ridha M Barbouche.   

Abstract

CFP32 is a Mycobacterium tuberculosis complex-restricted secreted protein that was previously reported to be present in a majority of sputum samples from patients with active tuberculosis (TB) and to stimulate serum antibody production. CFP32 (originally annotated as Rv0577 and also known as TB27.3) was therefore considered a good candidate target antigen for the rapid serodiagnosis of TB. However, the maximal sensitivity of CFP32 serorecognition may have been limited in earlier studies because recombinant CFP32 (rCFP32) produced in Escherichia coli was used as the test antibody-capture antigen, a potential shortcoming stemming from differences in bacterial protein posttranslational modifications. To further investigate the serodiagnostic potential of rCFP32 synthesized in different heterologous hosts, we expressed rCFP32 in the yeast Pichia pastoris. Compared to E. coli rCFP32, yeast rCFP32 showed a higher capacity to capture polyclonal antisera in Western blot studies. Likewise, yeast rCFP32 was significantly better recognized by the sera from TB patients and healthy Mycobacterium bovis bacillus Calmette-Guérin (BCG)-vaccinated individuals, by enzyme-linked immunosorbent assay (ELISA), than E. coli rCFP32. In subsequent testing, the yeast rCFP32-based antibody-capture ELISA had a sensitivity of 85% and a specificity of 98% for the discrimination of active TB cases (n = 40) from BCG vaccinees (n = 39). The sensitivity was surprisingly high for a single-antigen TB serodiagnostic test compared to tests using E. coli-expressed antigens. Overall, the trans-production of rCFP32 in P. pastoris significantly improved the serologic detection of CFP32-specific antibodies in patient sera, thereby offering a new, possibly better, modality for producing antigens of diagnostic potential for use in the development of immunoassays for both TB and other infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954231      PMCID: PMC1594712          DOI: 10.1128/JCM.02672-05

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  39 in total

1.  A comparison of seven tests for serological diagnosis of tuberculosis.

Authors:  S Pottumarthy; V C Wells; A J Morris
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern.

Authors:  C Horn; A Namane; P Pescher; M Rivière; F Romain; G Puzo; O Bârzu; G Marchal
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

3.  Homogeneity of antibody responses in tuberculosis patients.

Authors:  K Samanich; J T Belisle; S Laal
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Deglycosylation of the 45/47-kilodalton antigen complex of Mycobacterium tuberculosis decreases its capacity to elicit in vivo or in vitro cellular immune responses.

Authors:  F Romain; C Horn; P Pescher; A Namane; M Riviere; G Puzo; O Barzu; G Marchal
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

5.  High level expression of recombinant Mycobacterium tuberculosis culture filtrate protein CFP32 in Pichia pastoris.

Authors:  C Benabdesselem; M R Barbouche; M A Jarboui; K Dellagi; J L Ho; D M Fathallah
Journal:  Mol Biotechnol       Date:  2007-01       Impact factor: 2.695

6.  Combinatorial use of antibodies to secreted mycobacterial proteins in a host immune system-independent test for tuberculosis.

Authors:  C P Landowski; H P Godfrey; S I Bentley-Hibbert; X Liu; Z Huang; R Sepulveda; K Huygen; M L Gennaro; F H Moy; S A Lesley; M Haak-Frendscho
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

7.  Cloning and expression of immunoreactive antigens from Mycobacterium tuberculosis.

Authors:  R L Lim; L K Tan; W F Lau; M C Ming; R Dunn; H P Too; L Chan
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

8.  Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis.

Authors:  K M Samanich; M A Keen; V D Vissa; J D Harder; J S Spencer; J T Belisle; S Zolla-Pazner; S Laal
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

9.  Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia.

Authors:  S M Smith; M R Klein; A S Malin; J Sillah; K Huygen; P Andersen; K P McAdam; H M Dockrell
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

10.  A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements.

Authors:  L Wang; M O Turner; R K Elwood; M Schulzer; J M FitzGerald
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

View more
  5 in total

1.  Humoral immune responses of tuberculosis patients in Brazil indicate recognition of Mycobacterium tuberculosis MPT-51 and GlcB.

Authors:  Cristina Melo Cardoso Almeida; Arioldo C Vasconcelos; André Kipnis; Ana Lúcia Andrade; Ana Paula Junqueira-Kipnis
Journal:  Clin Vaccine Immunol       Date:  2008-01-16

2.  The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice.

Authors:  Dongqing Gu; Wei Chen; Youjun Mi; Xueli Gong; Tao Luo; Lang Bao
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-02-27       Impact factor: 3.848

3.  Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics.

Authors:  Sacha J Pidot; Jessica L Porter; Laurent Marsollier; Annick Chauty; Florence Migot-Nabias; Cyril Badaut; Angèle Bénard; Marie-Therese Ruf; Torsten Seemann; Paul D R Johnson; John K Davies; Grant A Jenkin; Gerd Pluschke; Timothy P Stinear
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

4.  Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur.

Authors:  Marcia Berrêdo-Pinho; Dario E Kalume; Paloma R Correa; Leonardo H F Gomes; Melissa P Pereira; Renata F da Silva; Luiz R R Castello-Branco; Wim M Degrave; Leila Mendonça-Lima
Journal:  BMC Microbiol       Date:  2011-04-20       Impact factor: 3.605

5.  Immunogenicity of heparin-binding hemagglutinin expressed by Pichia pastoris GS115 strain.

Authors:  Xindong Teng; Xiaoguang Chen; Ke Zhu; Hefei Xu
Journal:  Iran J Basic Med Sci       Date:  2018-02       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.